Driving Out Chronic Lymphocytic Leukemia With CAR T Cells

Mohamed A. Kharfan-Dabaja, Farah Yassine, Martha E. Gadd, Hong Qin

Research output: Contribution to journalReview articlepeer-review


Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in the Western hemisphere. The recent availability of novel targeted therapies, namely Bruton's tyrosine kinase, phosphoinositide-3 kinase, and BCL-2 inhibitors, have revolutionized the treatment algorithm for CLL but have not yet resulted in cure. Advances in the field of immuno-oncology and T cell engineering brought chimeric antigen receptor (CAR) T cell therapy from the laboratory to the clinic for treatment of B cell lymphoid malignancies and has improved the disease response and survival outcomes of various types of relapsed and/or refractory B cell lymphomas. While acknowledging that there are no approved CAR T cell therapies for CLL at this time, in this comprehensive review we explore novel targets for CAR T cell therapy in CLL and highlight the promising results of CAR T cell trials reported to date. Furthermore, we shed light on future areas of development, including multitarget CAR T cell products for this disease.

Original languageEnglish (US)
Pages (from-to)5-17
Number of pages13
JournalTransplantation and Cellular Therapy
Issue number1
StatePublished - Jan 2022


  • Chimeric antigen receptor T cell therapy
  • Chronic lymphocytic leukemia
  • Novel antigen target
  • Response rate
  • Survival

ASJC Scopus subject areas

  • Hematology
  • Transplantation
  • Immunology and Allergy
  • Cell Biology
  • Molecular Medicine
  • General Medicine


Dive into the research topics of 'Driving Out Chronic Lymphocytic Leukemia With CAR T Cells'. Together they form a unique fingerprint.

Cite this